Idacio (Adalimumab)

Adalimumab is a fully human monoclonal antibody that binds to tumor necrosis factor‑alpha (TNF‑α), a key cytokine in inflammatory pathways. By neutralising TNF‑α, it blocks the activation of TNF receptors, reducing downstream inflammatory signaling and the resulting tissue damage.

The dosing schedule for Idacio is set by the prescribing clinician based on the specific indication, patient weight, disease severity, and response to therapy. The prescriber decides the frequency and any dose adjustments after evaluating clinical outcomes.

Safety data for adalimumab in pregnancy and lactation are limited. The product is classified as pregnancy category unknown. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Idacio.

To order Idacio, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Idacio (adalimumab) is a fully human monoclonal antibody, whereas agents like etanercept are fusion proteins and infliximab is a chimeric antibody. All target TNF‑α but differ in molecular structure, dosing frequency, and immunogenicity profiles. Choice of therapy depends on clinical response, convenience, and physician preference.

Idacio should be stored refrigerated at 2‑8 °C. Keep the prefilled syringes in the original carton, protect them from light, and do not freeze or shake the product. If temporary temperature excursions occur, consult the product label before use.

Idacio is supplied as a 40 mg prefilled syringe for subcutaneous injection. The injection is given into the thigh, abdomen, or upper arm according to the prescriber’s instructions. Patients should rotate injection sites and follow aseptic technique to minimize local reactions.

The most serious risks include severe infections such as tuberculosis or bacterial sepsis, development of malignancies (e.g., lymphoma, skin cancer), hepatic injury, and rare demyelinating disorders. Patients should be monitored regularly for signs of infection, liver dysfunction, and any new neurological symptoms.

Idacio is contraindicated in individuals with known hypersensitivity to adalimumab or any excipients, active serious infections, untreated latent tuberculosis, or those receiving live vaccines. Caution is also advised for patients with severe heart failure, demyelinating disease, or a history of malignancy.